• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Oncopeptides seeks EU marketing authorization for multiple myeloma treatment

April 16, 2021 By Sean Whooley

OncopeptidesOncopeptides announced today that it submitted an application for European marketing authorization of its melflufen therapeutic.

Conditional marketing authorization from the European Medicines Agency (EMA) is the aim for the company after its pivotal phase 2 Horizon study provided positive outcomes with melflufen (melphalan flufenamide) in treating relapsed refractory multiple myeloma, according to a news release.

Stockholm-based Oncopeptides touts the drug, marketed as Pepaxto in the U.S., as the first anticancer peptide-drug conjugate approved for multiple myeloma.

Pepaxto links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound that helps to deliver the therapeutic into cells to leverage aminopeptidases that are overexpressed in multiple myeloma cells and cause the release of the cytotoxic agents. It is administered once a month in a 30-minute infusion process.

The FDA awarded accelerated FDA approval to Pepaxto in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma on Feb. 26 and the company subsequently launched the drug and reported that it was used to treat patients last month.

“Following Oncopeptides´ launch in the US, we are broadening our geographical footprint and submitting an application for conditional marketing authorization of melflufen in Europe ahead of expectations,” Oncopeptides CEO Marty J. Duvall said in the release. “This major milestone marks the commitment of our organization to bring hope to multiple myeloma patients around the world, through innovative science.”

“This is vitally important and supports the development of a dedicated organization across Europe,” added Oncopeptides GM of Europe Andrea Passalacqua. “We believe that melflufen may address a growing medical need in patients with relapsed refractory multiple myeloma in Europe. In order to help accomplishing this, we have also introduced an Early Access Program that offers eligible patients access to melflufen ahead of a potential marketing authorization.”

Filed Under: Featured, Oncology, Pharmaceuticals Tagged With: Oncopeptides

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS